Your Turnkey Solution
for Value-Based Purchasing
Arrangements

Why Us?My State Our Solution Get in touch

Is Your State Ready for the Future Impact on Budgets?

One high-cost cell and gene therapy can dramatically impact state budgets. The map below shows the cost to each state for one drug therapy for Sickle Cell Disease. The FDA predicts that 10-20 new cell and gene therapies could be approved each year by 2025.

Budget Impact, year 1 (million USD)

Alabama

$54.2

Washington, DC

$11,0

Florida

$144.9

Georgia

$115.4

Louisiana

$71.4

Maryland

$52.8

Budget Impact, year 1 (million USD)

Mississippi

$32.5

North Carolina

$65.5

South Carolina

$56.1

Virginia

$54.4

Total United States

$1241.0

Average

$65.8

WHY IS CMA/LYFEGEN YOUR PREFERRED PARTNER?

Get Better Purchasing Arrangements and Extract More Value

Proven ability 
to address the nuanced requirements of VBPAs

Highly specialized
expertise, focus and
capacity.

Leveraging a proven set
of unique technology
accelerators.

CMA/LYFEGEN’S COMPLETE VBPA SOLUTION

Comprehensive and Tailored to Your Needs

Identify

We identify high-cost drugs for VBPAs, propose customized VBPA models using our proprietary tools, simulating their viability based on expertise and feedback.

Negotiate

We validate and formalize VBPAs in line with your formats, assess data needs and prepare the VBPAs for signature.

Administer

We operationalize the VBPAs using our unique technology, automating data workflows, adjudication, and reporting, flexibly in line with your needs.

“Seeing how CMA and Lyfegen uses advanced technology to solve the immense problem of drug pricing & affordability by enabling value-based arrangements made my decision to join Lyfegen’s advisory board an easy one. I am excited about the value CMA and Lyfegen can deliver to healthcare payers, providers, and patients in the US and across the world.”

Jason Helgerson ‍

CEO of Helgerson Solutions
Group Former New York State Medicaid Director
Lyfegen Advisory Board

Let us walk you through our VBPA turnkey approach that can bring immediate value to your State Medicaid Program.

Jeffrey Wendth 

Vice President
Healthcare Solutions, CMA
jwendth@cma.com

Nico Mros 

CXO & Founder, 
Lyfegen
nico.mros@lyfegen.com

BOOK
NOW

Sources

https://ashpublications.org/bloodadvances/article/8/17/4658/517069/A-budget-impact-analysis-of-gene-therapy-for